Meri‐Sisko Vuoristo

Author

Meri‐Sisko Vuoristo

Tampere University Hospital

Also Known As

Meri-Sisko Vuoristo, Merisisko Vuoristo, Meri‐Sisko Vuoristo, Vuoristo, Meri-Sisko

Publications

410

Citations

H-Index

Concepts

All Affiliations

Tampere University Hospital Turku University Hospital Helsinki University Hospital Kuopio University Hospital

About

Meri‐Sisko Vuoristo is an author at Tampere University Hospital specializing in medicine, dermatology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	125
2	Immunology	3	3	70
3	Pathology	3	3	73
4	Health Sciences	1	1	34
5	Cancer Therapeutics	1	1	34

Meri‐Sisko Vuoristo

Publications

376

Citations

H-Index

Page 1

	Year	Citations
High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma Johanna Nikkola, Pia Vihinen, Meri‐Sisko Vuoristo, Clinical Cancer Research	2005	195
A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma Pia Vihinen, Micaela Hernberg, Meri‐Sisko Vuoristo, Melanoma Research	2010	56
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-?? in patients with advanced melanoma Meri‐Sisko Vuoristo, Marjo Hahka‐Kemppinen, L.-M. Parvinen, Melanoma Research OncologyRecombinant Interferon-Health SciencesSkin CancerMelanoma	2005	34
Serum VEGF-C is associated with metastatic site in patients with malignant melanoma Pia Vihinen, Johanna Hilli, Meri‐Sisko Vuoristo, Acta Oncologica Tumor BiologyMedicineMelanomaImmunologySerum Vegf-c	2006	31
Serum angiogenin levels predict treatment response in patients with stage IV melanoma Pia Vihinen, Minna Kallioinen, Meri‐Sisko Vuoristo, Clinical & Experimental Metastasis MedicineMelanomaTreatment ResponsePathologyDermatology	2007	21
The polymorphisms of interleukin-10 gene influence the prognosis of patients with advanced melanoma Meri‐Sisko Vuoristo Cancer Genetics and Cytogenetics MedicineInterleukin-10 Gene InfluenceGenetic EpidemiologyImmunologyPathology	2007	21
A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma Meri‐Sisko Vuoristo, Ismo T. Jantunen, Seppo Pyrhönen, European Journal of Cancer UrologyCancer ImmunosurveillanceGenitourinary CancerMelanomaImmunology	1994	18

Page 1